Hepatic fibrosis represents a dynamic wound-healing response of the liver that becomes pathologic when injury is persistent. Regardless of the cause—viral hepatitis, alcohol, NASH, autoimmune disease, or toxic injury—the process converges on a final common pathway: activation of hepatic stellate cells (HSCs) into contractile, ECM-producing myofibroblasts. This transition is driven by inflammatory cytokines, oxidative stress, and changes in the extracellular matrix environment.
The article describes fibrosis as neither irreversible nor linear. Instead, it is a bidirectional process, where progression and regression depend on the balance between fibrogenic signals and mechanisms that promote matrix degradation. In regression, inactivated HSCs undergo apoptosis, senescence, or reversion to a quiescent phenotype, while matrix-remodelling enzymes reduce the dense collagen network.
To build reliable conclusions, the review synthesizes findings from human trials, animal models (such as CClâ‚„ and bile-duct ligation), and mechanistic in-vitro studies. It selects studies with strong methodological design, appropriate fibrosis staging systems (like METAVIR or Ishak), and validated non-invasive assessment techniques including elastography.
Overall, the aim is to integrate experimental and clinical evidence to clarify how fibrosis develops, how it can reverse, and which biological nodes represent the most promising therapeutic targets. The work emphasizes that modern understanding of liver fibrosis has shifted from viewing it as a static, end-stage scarring process to recognizing it as a modifiable, targetable disease state, opening new opportunities for anti-fibrotic therapy and early diagnosis.
Publication Date: 2026-06-13